Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP,
Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris
F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct ofin vitro
and in vivo drug–drug interaction studies: a Pharmaceutical Research and
Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003a;31:
815–832.
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP,
Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris
F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct ofin vitro
andin vivodrug–drug interaction studies: a PhRMA perspective. J Clin Pharmacol
2003b;43:443–469.
Brown HS, Ito K, Galetin A, Houston JB. Prediction ofin vivodrug–drug interactions
fromin vitrodata: impact of incorporating parallel pathways of drug elimination and
inhibitor absorption rate constant. Br J Clin Pharmacol 2005;60:508–518.
Bu HZ, Knuth K, Magis L, Teitelbaum P. High-throughput cytochrome P450 (CYP)
inhibition screening via cassette probe-dosing strategy: III. Validation of a direct
injection/on-line guard cartridge extraction-tandem mass spectrometry method for
CYP2C19 inhibition evaluation. J Pharm Biomed Anal 2001a;25:437–442.
Bu HZ, Magis L, Knuth K, Teitelbaum P. High-throughput cytochrome P450 (CYP)
inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous
evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6,
3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001b;15:741–748.
Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver
microsomal cytochrome P-450 isoforms by L-754,394, an investigational human
immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995;275:1527–
1534.
Cohen LH, Remley MJ, Raunig D, Vaz ADN.In vitrodrug interactions of cytochrome
p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos
2003;31:1005–1015.
Correia MA. Cytochrome P450 turnover. Methods Enzymol 1991;206:315–325.
Crespi CL, Stresser DM. Fluorometric screening for metabolism-based drug–drug
interactions. J Pharmacol Toxicol Methods 2000;44:325–331.
DiMarco A, Marcucci I, Verdirame M, Perez J, Sanchez M, Pelaez F, Chaudhary A,
Laufer R. Development and validation of a high-throughput radiometric CYP3A4/5
inhibition assay using tritiated testosterone. Drug Metab Dispos 2005;33:349–358.
Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. A method for the
simultaneous evaluation of the activities of seven major human drug-metabolizing
cytochrome P450s using anin vitrococktail of probe substrates and fast gradient
liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001;29:23–29.
Donato MT, Jimenez N, Castell JV, Gomez-Lechon MJ. Fluorescence-based assays for
screening nine cytochrome P450 (P450) activities in intact cells expressing individual
human P450 enzymes. Drug Metab Dispos 2004;32:699–706.
Draper AJ, Madan A, Latham J, Parkinson A. Development of a non-high pressure
liquid chromatography assay to determine [^14 C]chlorzoxazone 6-hydroxylase
(CYP2E1) activity in human liver microsomes. Drug Metab Dispos 1998a;26:305–
312.
REFERENCES 539